OTC · IMVIF
IMV Inc.
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · ADYX · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Adynxx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Adynxx, Inc.’s forward annual dividend is $75.60 per share, paid monthly. The forward yield is 75,600,000.0% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Adynxx, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:33 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
9 Meters Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
BIMI International Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
FusionPharm, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Bionik Laboratories Corp.: Healthcare · Medical - Care Facilities.
$0.00$0.00 (0.0%)
BG Medicine, Inc.: Healthcare · Medical - Instruments & Supplies.
$0.00$0.00 (0.0%)
Millennium Sustainable Ventures Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$0.00-$0.00 (0.0%)
Omnimmune Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 0.0% below the high.
